Paradigm Biocapital Advisors as of Sept. 30, 2025
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 34 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 13.0 | $456M | 5.3M | 86.48 | |
| Merus N V Call Option (MRUS) | 12.5 | $440M | 4.7M | 94.15 | |
| Arcellx Common Stock (ACLX) | 10.9 | $382M | 4.6M | 82.10 | |
| Revolution Medicines (RVMD) | 8.3 | $291M | 6.2M | 46.70 | |
| Tarsus Pharmaceuticals (TARS) | 4.5 | $158M | 2.7M | 59.43 | |
| Vaxcyte (PCVX) | 3.9 | $136M | 3.8M | 36.02 | |
| Abivax Sa Sponsored Ads (ABVX) | 3.8 | $133M | 1.6M | 84.90 | |
| Genmab A/s Sponsored Ads (GMAB) | 3.3 | $117M | 3.8M | 30.67 | |
| Agios Pharmaceuticals Call Option (AGIO) | 3.3 | $115M | 2.9M | 40.14 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.0 | $106M | 2.6M | 41.65 | |
| Spdr Series Trust S&p Biotech Put Option (XBI) | 2.8 | $100M | 1.0M | 100.20 | |
| Edgewise Therapeutics (EWTX) | 2.8 | $100M | 6.2M | 16.22 | |
| Cidara Therapeutics Com New (CDTX) | 2.6 | $92M | 961k | 95.76 | |
| Urogen Pharma (URGN) | 2.4 | $84M | 4.2M | 19.95 | |
| Scholar Rock Hldg Corp (SRRK) | 2.1 | $75M | 2.0M | 37.24 | |
| Janux Therapeutics (JANX) | 2.0 | $71M | 2.9M | 24.44 | |
| Olema Pharmaceuticals (OLMA) | 1.9 | $67M | 6.8M | 9.79 | |
| Apogee Therapeutics (APGE) | 1.7 | $61M | 1.5M | 39.73 | |
| Miragen Therapeutics (VRDN) | 1.6 | $56M | 2.6M | 21.58 | |
| Alkermes SHS (ALKS) | 1.5 | $52M | 1.7M | 30.00 | |
| Lenz Therapeutics (LENZ) | 1.4 | $50M | 1.1M | 46.58 | |
| Pharvaris N V (PHVS) | 1.3 | $46M | 1.8M | 24.95 | |
| Cogent Biosciences (COGT) | 1.3 | $45M | 3.2M | 14.36 | |
| Ocular Therapeutix (OCUL) | 1.2 | $41M | 3.5M | 11.69 | |
| Bridgebio Pharma (BBIO) | 1.0 | $36M | 684k | 51.94 | |
| Erasca (ERAS) | 0.8 | $30M | 14M | 2.18 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.8 | $29M | 2.0M | 14.24 | |
| Tango Therapeutics (TNGX) | 0.7 | $26M | 3.1M | 8.40 | |
| Amylyx Pharmaceuticals (AMLX) | 0.7 | $26M | 1.9M | 13.59 | |
| Spyre Therapeutics Com New (SYRE) | 0.7 | $25M | 1.5M | 16.76 | |
| Dyne Therapeutics (DYN) | 0.7 | $24M | 1.9M | 12.65 | |
| Bridgebio Oncology Therapeut Com New | 0.6 | $22M | 1.9M | 11.58 | |
| Disc Medicine (IRON) | 0.5 | $16M | 248k | 66.08 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 0.3 | $10M | 373k | 28.00 |
